Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 119098
Published online Sep 15, 2026. doi: 10.4251/wjgo.119098
Published online Sep 15, 2026. doi: 10.4251/wjgo.119098
Letter to the Editor: Beyond the mechanism: MiR-206 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma after incomplete radiofrequency ablation
Yan Xu, Xiao-Bing Huang, Yong-Gang He, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Author contributions: Xu Y drafted and edited the manuscript; Huang XB revised the manuscript; He YG contributed to the conceptualization of the study and the critical review of the manuscript for important intellectual content; and all authors read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Yong-Gang He, Associate Chief Physician, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Shapingba District, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn
Received: January 26, 2026
Revised: February 11, 2026
Accepted: April 13, 2026
Published online: September 15, 2026
Processing time: 218 Days and 21.2 Hours
Revised: February 11, 2026
Accepted: April 13, 2026
Published online: September 15, 2026
Processing time: 218 Days and 21.2 Hours
Core Tip
Core Tip: This commentary extends the findings from a recent article by proposing two concrete translational applications for microRNA-206 in the management of hepatocellular carcinoma: (1) As a preoperative biomarker to stratify recurrence risk before ablation; and (2) As a therapeutic agent administered locally by a nanocarrier during or after radiofrequency ablation to prevent recurrence. The potential duality of microRNA-206 could transform the standard of care for patients with high-risk hepatocellular carcinoma.